PMID- 31816162
OWN - NLM
STAT- MEDLINE
DCOM- 20210518
LR  - 20210518
IS  - 1879-0844 (Electronic)
IS  - 1388-9842 (Linking)
VI  - 22
IP  - 2
DP  - 2020 Feb
TI  - European Society of Cardiology/Heart Failure Association position paper on the 
      role and safety of new glucose-lowering drugs in patients with heart failure.
PG  - 196-213
LID - 10.1002/ejhf.1673 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is common in patients with heart failure (HF) and 
      associated with considerable morbidity and mortality. Significant advances have 
      recently occurred in the treatment of T2DM, with evidence of several new 
      glucose-lowering medications showing either neutral or beneficial cardiovascular 
      effects. However, some of these agents have safety characteristics with strong 
      practical implications in HF [i.e. dipeptidyl peptidase-4 (DPP-4) inhibitors, 
      glucagon-like peptide-1 receptor agonists (GLP-1 RA), and sodium-glucose 
      co-transporter type 2 (SGLT-2) inhibitors]. Regarding safety of DPP-4 inhibitors, 
      saxagliptin is not recommended in HF because of a greater risk of HF 
      hospitalisation. There is no compelling evidence of excess HF risk with the other 
      DPP-4 inhibitors. GLP-1 RAs have an overall neutral effect on HF outcomes. 
      However, a signal of harm suggested in two small trials of liraglutide in 
      patients with reduced ejection fraction indicates that their role remains to be 
      defined in established HF. SGLT-2 inhibitors (empagliflozin, canagliflozin and 
      dapagliflozin) have shown a consistent reduction in the risk of HF 
      hospitalisation regardless of baseline cardiovascular risk or history of HF. 
      Accordingly, SGLT-2 inhibitors could be recommended to prevent HF hospitalisation 
      in patients with T2DM and established cardiovascular disease or with multiple 
      risk factors. The recently completed trial with dapagliflozin has shown a 
      significant reduction in cardiovascular mortality and HF events in patients with 
      HF and reduced ejection fraction, with or without T2DM. Several ongoing trials 
      will assess whether the results observed with dapagliflozin could be extended to 
      other SGLT-2 inhibitors in the treatment of HF, with either preserved or reduced 
      ejection fraction, regardless of the presence of T2DM. This position paper aims 
      to summarise relevant clinical trial evidence concerning the role and safety of 
      new glucose-lowering therapies in patients with HF.
CI  - (c) 2019 The Authors. European Journal of Heart Failure (c) 2019 European Society of 
      Cardiology.
FAU - Seferovic, Petar M
AU  - Seferovic PM
AD  - Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
AD  - Serbian Academy of Sciences and Arts, Belgrade, Serbia.
FAU - Coats, Andrew J S
AU  - Coats AJS
AD  - Pharmacology, Centre of Clinical and Experimental Medicine, IRCCS San Raffaele 
      Pisana, Rome, Italy.
FAU - Ponikowski, Piotr
AU  - Ponikowski P
AD  - Centre for Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.
FAU - Filippatos, Gerasimos
AU  - Filippatos G
AD  - University of Cyprus Medical School, Nicosia, Cyprus.
AD  - Athens University Hospital Attikon, National and Kapodistrian University of 
      Athens, Athens, Greece.
FAU - Huelsmann, Martin
AU  - Huelsmann M
AD  - Division of Cardiology, Department of Medicine II, Medical University of Vienna, 
      Vienna, Austria.
FAU - Jhund, Pardeep S
AU  - Jhund PS
AD  - British Heart Foundation, Cardiovascular Research Centre, University of Glasgow, 
      Glasgow, UK.
FAU - Polovina, Marija M
AU  - Polovina MM
AD  - Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
AD  - Department of Cardiology, Clinical Centre of Serbia, Belgrade, Serbia.
FAU - Komajda, Michel
AU  - Komajda M
AD  - Institute of Cardiometabolism and Nutrition (ICAN), Pierre et Marie Curie 
      University, Paris VI, La Pitie-Salpetriere Hospital, Paris, France.
FAU - Seferovic, Jelena
AU  - Seferovic J
AD  - Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
AD  - Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Centre, 
      Belgrade, Serbia.
FAU - Sari, Ibrahim
AU  - Sari I
AD  - Department of Cardiology, Faculty of Medicine, Marmara University, Istanbul, 
      Turkey.
FAU - Cosentino, Francesco
AU  - Cosentino F
AD  - Cardiology Unit, Department of Medicine, Karolinska Institute and Karolinska 
      University Hospital, Stockholm, Sweden.
FAU - Ambrosio, Giuseppe
AU  - Ambrosio G
AD  - Division of Cardiology, University of Perugia, Perugia, Italy.
FAU - Metra, Marco
AU  - Metra M
AD  - Cardiology, Department of Medical and Surgical Specialties, Radiological 
      Sciences, and Public Health, University of Brescia, Brescia, Italy.
FAU - Piepoli, Massimo
AU  - Piepoli M
AD  - Heart Failure Unit, Cardiology, G. da Saliceto Hospital, Piacenza, Italy.
FAU - Chioncel, Ovidiu
AU  - Chioncel O
AD  - University of Medicine Carol Davila, Bucharest, Romania.
AD  - Emergency Institute for Cardiovascular Diseases, Bucharest, Romania.
FAU - Lund, Lars H
AU  - Lund LH
AD  - Department of Medicine, Karolinska Institutet, and Heart and Vascular Theme, 
      Karolinska University Hospital, Stockholm, Sweden.
FAU - Thum, Thomas
AU  - Thum T
AD  - Hannover Medical School, Institute of Molecular and Translational Therapeutic 
      Strategies, Hannover, Germany.
FAU - De Boer, Rudolf A
AU  - De Boer RA
AD  - Department of Cardiology, University Medical Center Groningen, University of 
      Groningen, Groningen, The Netherlands.
FAU - Mullens, Wilfried
AU  - Mullens W
AD  - Faculty of Medicine and Life Sciences, BIOMED - Biomedical Research Institute, 
      Hasselt University, Diepenbeek, Belgium.
AD  - Department of Cardiology, Ziekenhuis Oost, Genk, Belgium.
FAU - Lopatin, Yuri
AU  - Lopatin Y
AD  - Regional Cardiology Centre Volgograd, Volgograd State Medical University, 
      Volgograd, Russia.
FAU - Volterrani, Maurizio
AU  - Volterrani M
AD  - Department of Cardiology, IRCCS San Raffaele Pisana, Rome, Italy.
FAU - Hill, Loreena
AU  - Hill L
AD  - School of Nursing and Midwifery, Queen's University Belfast, Belfast, UK.
FAU - Bauersachs, Johann
AU  - Bauersachs J
AD  - Department of Cardiology and Angiology, Medical School Hannover, Hannover, 
      Germany.
FAU - Lyon, Alexander
AU  - Lyon A
AD  - National Heart and Lung Institute, Imperial College London and Royal Brompton 
      Hospital, London, UK.
FAU - Petrie, Mark C
AU  - Petrie MC
AD  - Institute of Cardiovascular and Medical Sciences, British Heart Foundation 
      Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
FAU - Anker, Stefan
AU  - Anker S
AD  - Department of Cardiology (CVK), Berlin Institute of Health Center for 
      Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) 
      partner site Berlin, Charite Universitatsmedizin Berlin, Berlin, Germany.
FAU - Rosano, Giuseppe M C
AU  - Rosano GMC
AD  - Department of Medical Sciences, IRCCS San Raffaele Pisana, Rome, Italy.
LA  - eng
PT  - Journal Article
DEP - 20191209
PL  - England
TA  - Eur J Heart Fail
JT  - European journal of heart failure
JID - 100887595
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0SAC974Z85 (Canagliflozin)
RN  - 1ULL0QJ8UC (dapagliflozin)
RN  - 839I73S42A (Liraglutide)
RN  - HDC1R2M35U (empagliflozin)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Benzhydryl Compounds
MH  - Canagliflozin
MH  - Cardiology/*standards
MH  - Clinical Trials as Topic
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy/epidemiology
MH  - Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
MH  - Europe
MH  - Glucagon-Like Peptide-1 Receptor/antagonists & inhibitors
MH  - Glucose
MH  - Glucosides
MH  - *Heart Failure/drug therapy/epidemiology
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Liraglutide
MH  - Societies, Medical
MH  - Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
OTO - NOTNLM
OT  - Cardiovascular risk
OT  - Clinical trial
OT  - Dipeptidyl peptidase-4 inhibitor
OT  - Glucagon-like peptide-1 receptor agonist
OT  - Heart failure
OT  - Hospitalisation
OT  - Sodium-glucose co-transporter type 2 inhibitor
OT  - Type 2 diabetes mellitus
EDAT- 2019/12/10 06:00
MHDA- 2021/05/19 06:00
CRDT- 2019/12/10 06:00
PHST- 2019/08/01 00:00 [received]
PHST- 2019/10/09 00:00 [revised]
PHST- 2019/10/16 00:00 [accepted]
PHST- 2019/12/10 06:00 [pubmed]
PHST- 2021/05/19 06:00 [medline]
PHST- 2019/12/10 06:00 [entrez]
AID - 10.1002/ejhf.1673 [doi]
PST - ppublish
SO  - Eur J Heart Fail. 2020 Feb;22(2):196-213. doi: 10.1002/ejhf.1673. Epub 2019 Dec 
      9.